FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Keane

Research Profile

Disorders

Anatomy

Chemicals & Drugs

Living Beings

Physiology

Cell Divisions

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
Andrew M Tershakovec; William F Keane; Zhongxin Zhang; Paulette A Lyle; Gerald B Appel; Janet B McGill; Hans-Henrik Parving; Mark E Cooper; Shahnaz Shahinfar; Barry M Brenner
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Wouter B A Eijkelkamp; Zhongxin Zhang; Giuseppe Remuzzi; Hans-Henrik Parving; Mark E Cooper; William F Keane; Shahnaz Shahinfar; Gilbert W Gleim; Matthew R Weir; Barry M Brenner; Dick De Zeeuw
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Wouter B A Eijkelkamp; Zhongxin Zhang; Barry M Brenner; Mark E Cooper; Richard B Devereux; Björn Dahlöf; Hans Ibsen; William F Keane; Lars H Lindholm; Michael H Olsen; Hans-Henrik Parving; Giuseppe Remuzzi; Shahnaz Shahinfar; Steven M Snapinn; Kristian Wachtell; Dick De Zeeuw
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Keane (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Andrew M Tershakovec; William F Keane; Zhongxin Zhang; Paulette A Lyle; Gerald B Appel; Janet B McGill; Hans-Henrik Parving; Mark E Cooper; Shahnaz Shahinfar; Barry M Brenner
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Diabetes care 2008;31(3):445-7.
2007: Wouter B A Eijkelkamp; Zhongxin Zhang; Giuseppe Remuzzi; Hans-Henrik Parving; Mark E Cooper; William F Keane; Shahnaz Shahinfar; Gilbert W Gleim; Matthew R Weir; Barry M Brenner; Dick De Zeeuw
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Journal of the American Society of Nephrology : JASN 2007;18(5):1540-6.
2007: Wouter B A Eijkelkamp; Zhongxin Zhang; Barry M Brenner; Mark E Cooper; Richard B Devereux; Björn Dahlöf; Hans Ibsen; William F Keane; Lars H Lindholm; Michael H Olsen; Hans-Henrik Parving; Giuseppe Remuzzi; Shahnaz Shahinfar; Steven M Snapinn; Kristian Wachtell; Dick De Zeeuw
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.
Journal of hypertension 2007;25(4):871-6.
2006: Kiyoshi Kurokawa; Juliana C N Chan; Mark E Cooper; William F Keane; Shahnaz Shahinfar; Zhongxin Zhang
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Clinical and experimental nephrology 2006;10(3):193-200.
2006: William F Keane; Zhongxin Zhang; Paulette A Lyle; Mark E Cooper; Dick De Zeeuw; Jean-Pierre Grunfeld; James P Lash; Janet B McGill; William E Mitch; Giuseppe Remuzzi; Shahnaz Shahinfar; Steven M Snapinn; Robert D Toto; Barry M Brenner
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
Clinical journal of the American Society of Nephrology : CJASN 2006;1(4):761-7.
2006: Shahnaz Shahinfar; Paulette A Lyle; Zhongxin Zhang; William F Keane; Barry M Brenner
Losartan: lessons learned from the RENAAL study.
Expert opinion on pharmacotherapy 2006;7(5):623-30.
2006: George W Carides; Shahnaz Shahinfar; Erik J Dasbach; William F Keane; William C Gerth; Charles M Alexander; William H Herman; Barry M Brenner
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
PharmacoEconomics 2006;24(6):549-58.
2005: William F Keane; Paulette A Lyle
Kidney disease and cardiovascular disease: implications of dyslipidemia.
Cardiology clinics 2005;23(3):363-72.
2005: Zhongxin Zhang; Shahnaz Shahinfar; William F Keane; Denise Ramjit; Tania Z Dickson; Gilbert W Gleim; Carl Erik Mogensen; Dick De Zeeuw; Barry M Brenner; Steven M Snapinn
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Journal of the American Society of Nephrology : JASN 2005;16(6):1775-80.
2005: Shahnaz Shahinfar; Tania Z Dickson; Zhongxin Zhang; William F Keane; Barry M Brenner
Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.
Kidney international. Supplement 2005;(93):S48-51.
2004: Charles M Alexander; Paulette A Lyle; William F Keane; George W Carides; Zhongxin Zhang; Shahnaz Shahinfar
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Kidney international. Supplement 2004;(92):S115-7.
2004: Anupama Mohanram; Zhongxin Zhang; Shahnaz Shahinfar; William F Keane; Barry M Brenner; Robert D Toto
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
Kidney international 2004;66(3):1131-8.
2004: Dick De Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steven M Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Circulation 2004;110(8):921-7.
2004: Dick De Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steven M Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Kidney international 2004;65(6):2309-20.
2003: William F Keane; Barry M Brenner; Dick De Zeeuw; Jean-Pierre Grunfeld; Janet McGill; William E Mitch; Artur B Ribeiro; Shahnaz Shahinfar; Roger L Simpson; Steven M Snapinn; Robert D Toto
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.
Kidney international 2003;63(4):1499-507.
2003: William F Keane; Paulette A Lyle
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2003;41(3 Suppl 1):S22-5.
2003: William H Herman; Shahnaz Shahinfar; George W Carides; Erik J Dasbach; William C Gerth; Charles M Alexander; John R Cook; William F Keane; Barry M Brenner
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Diabetes care 2003;26(3):683-7.
2001: T Nemoto; Melissa J Burne; Frank Daniels; Michael P O'Donnell; J Crosson; K Berens; A Issekutz; Bertram L Kasiske; William F Keane; Hamid Rabb
Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure.
Kidney international 2001;60(6):2205-14.
2001: HH Parving; B M Brenner; M E Cooper; D de Zeeuw; William F Keane; W E Mitch; G Remuzzi; Steven M Snapinn; Z Zhang; Shahnaz Shahinfar
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Ugeskrift for laeger 2001;163(40):5514-9.
2001: Barry M Brenner; M E Cooper; Dick De Zeeuw; William F Keane; W E Mitch; Hans-Henrik Parving; Giuseppe Remuzzi; Steven M Snapinn; Zhongxin Zhang; Shahnaz Shahinfar
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine 2001;345(12):861-9.
2001: William F Keane; Barry M Brenner; A Mazzu; A Agro
The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;37(1 Suppl 2):S48-53.
2001: T Nemoto; N Yokota; William F Keane; Hamid Rabb
Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure.
Kidney international 2001;59(1):246-51.
2000: Barry M Brenner; M E Cooper; Dick De Zeeuw; Jean-Pierre Grunfeld; William F Keane; K Kurokawa; J B McGill; W E Mitch; Hans-Henrik Parving; Giuseppe Remuzzi; Artur B Ribeiro; M D Schluchter; D Snavely; Zhongxin Zhang; R Simpson; Denise Ramjit; Shahnaz Shahinfar
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
Journal of the renin-angiotensin-aldosterone system : JRAAS 2000;1(4):328-35.
2000: William F Keane
Proteinuria: its clinical importance and role in progressive renal disease.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2000;35(4 Suppl 1):S97-105.
2000: Ziad A Massy; Y Kim; Carlos Guijarro; Bertram L Kasiske; William F Keane; Michael P O'Donnell
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin.
Biochemical and biophysical research communications 2000;267(2):536-40.
1999: H Oda; Bertram L Kasiske; Michael P O'Donnell; William F Keane
Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells.
Kidney international. Supplement 1999;71():S202-5.
1999: Carlos Guijarro; Luis M Blanco-Colio; Ziad A Massy; Michael P O'Donnell; Bertram L Kasiske; William F Keane; jesus egido
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Kidney international. Supplement 1999;71():S88-91.
1999: Ziad A Massy; Carlos Guijarro; H Oda; Bertram L Kasiske; William F Keane; Michael P O'Donnell
Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis.
Kidney international. Supplement 1999;71():S80-3.
1999: Ziad A Massy; Carlos Guijarro; Michael P O'Donnell; Y Kim; C E Kashtan; jesus egido; Bertram L Kasiske; William F Keane
The central role of nuclear factor-kappa B in mesangial cell activation.
Kidney international. Supplement 1999;71():S76-9.
1999: H Oda; William F Keane
Recent advances in statins and the kidney.
Kidney international. Supplement 1999;71():S2-5.
1998: Michael P O'Donnell; C C Chao; G Gekker; KS Modi; Bertram L Kasiske; William F Keane
Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes.
Kidney international 1998;53(3):593-7.
1998: H Oda; William F Keane
Lipid abnormalities in end stage renal disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1998;13 Suppl 1():45-9.
1998: Y S Park; Carlos Guijarro; Y Kim; Ziad A Massy; Bertram L Kasiske; William F Keane; Michael P O'Donnell
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1998;31(1):190-4.
1997: Michael P O'Donnell; Gretchen S Crary; H Oda; Bertram L Kasiske; J R Powell; William F Keane
Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.
Kidney international. Supplement 1997;63():S218-20.
1997: H Oda; William F Keane
Lipids in progression of renal disease.
Kidney international. Supplement 1997;62():S36-8.
1997: William F Keane
Derangement of lipid metabolism and its management in renal transplant patients.
Mineral and electrolyte metabolism 1997;23(3-6):166-9.
1997: William F Keane; A Polis; D Wolf; E Faison; Shahnaz Shahinfar
The long-term tolerability of enalapril in hypertensive patients with renal impairment.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1997;12 Suppl 2():75-81.
1997: Michael P O'Donnell; Ziad A Massy; Carlos Guijarro; Bertram L Kasiske; Y Kim; William F Keane
Isoprenoids, Ras and proliferative glomerular disease.
Contributions to nephrology 1997;120():219-27.
1997: Carlos Guijarro; Y Kim; Bertram L Kasiske; Ziad A Massy; Michael P O'Donnell; C E Kashtan; William F Keane
Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines.
Contributions to nephrology 1997;120():210-8.
1997: Ziad A Massy; Carlos Guijarro; Michael P O'Donnell; Bertram L Kasiske; William F Keane
Regulation of mesangial cell proliferation by the mevalonate pathway.
Contributions to nephrology 1997;120():191-6.
1996: William F Keane; S R Alexander; G R Bailie; Elisabeth Wilhelmina Boeschoten; R Gokal; T A Golper; Clifford Holmes; C C Huang; Y Kawaguchi; B Piraino; M Riella; Franz Schaefer; S Vas
Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 1996;16(6):557-73.
1996: Carlos Guijarro; Y Kim; C M Schoonover; Ziad A Massy; Michael P O'Donnell; Bertram L Kasiske; William F Keane; C E Kashtan
Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1996;11(6):990-6.
1996: Ziad A Massy; William F Keane; Bertram L Kasiske
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?
Lancet 1996;347(8994):102-3.
1996: William F Keane
Lipids and progressive renal failure.
Wiener klinische Wochenschrift 1996;108(14):420-4.
1996: William F Keane; Carlos Guijarro
Lipids and progressive renal failure.
Contributions to nephrology 1996;118():17-23.
1996: Ziad A Massy; William F Keane
Pathogenesis of atherosclerosis.
Seminars in nephrology 1996;16(1):12-20.
1996: Carlos Guijarro; William F Keane
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
Mineral and electrolyte metabolism 1996;22(1-3):147-52.
1995: Michael P O'Donnell; Bertram L Kasiske; Ziad A Massy; Carlos Guijarro; Suzanne K Swan; William F Keane
Isoprenoids and Ras: potential role in chronic rejection.
Kidney international. Supplement 1995;52():S29-33.
1995: Suzanne K Swan; Gretchen S Crary; Carlos Guijarro; Michael P O'Donnell; William F Keane; Bertram L Kasiske
Immunosuppressive effects of leflunomide in experimental chronic vascular rejection.
Transplantation 1995;60(8):887-90.
1995: Gretchen S Crary; Suzanne K Swan; Michael P O'Donnell; Bertram L Kasiske; S A Katz; William F Keane
The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats.
Journal of the American Society of Nephrology : JASN 1995;6(4):1295-9.
1995: S Y Kim; Carlos Guijarro; Michael P O'Donnell; Bertram L Kasiske; Y Kim; William F Keane
Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin.
Kidney international 1995;48(2):363-71.
1995: Carlos Guijarro; Bertram L Kasiske; Y Kim; Michael P O'Donnell; H S Lee; William F Keane
Early glomerular changes in rats with dietary-induced hypercholesterolemia.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1995;26(1):152-61.
1995: M O Wong; M A Eldon; William F Keane; Dietrich Türck; HN Bockbrader; B A Underwood; Allen J Sedman; C E Halstenson
Disposition of gabapentin in anuric subjects on hemodialysis.
Journal of clinical pharmacology 1995;35(6):622-6.
1995: EF Foote; D R Lee; A Karim; William F Keane; C E Halstenson
Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function.
Journal of clinical pharmacology 1995;35(4):384-9.
1995: EF Foote; Z M Look; P Giles; William F Keane; C E Halstenson
The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1995;25(3):420-5.
1994: William F Keane; Allan J Collins
Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1994;24(6):1010-8.
1994: C E Halstenson; M O Wong; C A Johnson; S W Zimmerman; J J Onorato; William F Keane; M Doepner; L Sia; K Tantillo; S Bansal
Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.
Journal of clinical pharmacology 1994;34(12):1208-17.
1994: Bertram L Kasiske; Michael P O'Donnell; Y Kim; D Atluru; William F Keane
Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
Kidney international. Supplement 1994;45():S51-3.
1994: William F Keane
Effect of lipids on glomerular injury and progression of renal disease.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 1994;56(2):91-104.
1993: William F Keane; Michael P O'Donnell; Bertram L Kasiske; Y Kim
Oxidative modification of low-density lipoproteins by mesangial cells.
Journal of the American Society of Nephrology : JASN 1993;4(2):187-94.
1993: Michael P O'Donnell; Bertram L Kasiske; Y Kim; Paul G Schmitz; William F Keane
Lovastatin retards the progression of established glomerular disease in obese Zucker rats.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;22(1):83-9.
1993: William F Keane; Bertram L Kasiske; Michael P O'Donnell; Y Kim
Hypertension, hyperlipidemia, and renal damage.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;21(5 Suppl 2):43-50.
1993: William F Keane; E D Everett; T A Golper; R Gokal; C Halstenson; Y Kawaguchi; M Riella; S Vas; Henri A Verbrugh
Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 1993;13(1):14-28.
1993: Michael P O'Donnell; Bertram L Kasiske; Y Kim; D Atluru; William F Keane
Lovastatin inhibits proliferation of rat mesangial cells.
The Journal of clinical investigation 1993;91(1):83-7.
1993: J V St Peter; M E Brady; EF Foote; K A Dandekar; L Smaldone; J L Pykkonen; William F Keane; C E Halstenson
The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.
European journal of clinical pharmacology 1993;45(1):59-63.
1993: Michael P O'Donnell; Bertram L Kasiske; Y Kim; D Atluru; William F Keane
The mevalonate pathway: importance in mesangial cell biology and glomerular disease.
Mineral and electrolyte metabolism 1993;19(3):173-9.
1992: L Bell; C E Halstenson; C J Halstenson; M Macres; William F Keane
Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia.
Archives of internal medicine 1992;152(12):2441-4.
1992: Michael P O'Donnell; Bertram L Kasiske; SA Katz; Paul G Schmitz; William F Keane
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats.
Hypertension 1992;20(5):651-8.
1992: William F Keane; J V St Peter; Bertram L Kasiske
Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
Kidney international. Supplement 1992;38():S134-41.
1992: C E Halstenson; M O Wong; C S Herman; KL Heim-Duthoy; M A Teal; M B Affrime; J H Kelloway; William F Keane; Walid Awni
Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease.
Antimicrobial agents and chemotherapy 1992;36(9):1832-6.
1992: Paul G Schmitz; Michael P O'Donnell; Bertram L Kasiske; SA Katz; William F Keane
Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril.
The American journal of physiology 1992;263(3 Pt 2):F496-502.
1992: Bertram L Kasiske; Michael P O'Donnell; William F Keane
The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury.
Hypertension 1992;19(1 Suppl):I110-5.
1991: J S Kelloway; Walid Awni; C C Lin; J Lim; M B Affrime; William F Keane; G R Matzke; C E Halstenson
Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.
Antimicrobial agents and chemotherapy 1991;35(11):2267-74.
1991: William F Keane; C A Hirata-Dulas; M L Bullock; Arthur L Ney; David R P Guay; R S Kalil; C A Dinarello; C E Halstenson; Phillip K Peterson
Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure.
Journal of the American Society of Nephrology : JASN 1991;2(4):841-7.
1991: Paul G Schmitz; Michael P O'Donnell; Bertram L Kasiske; William F Keane
Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation.
The Journal of laboratory and clinical medicine 1991;118(2):129-35.
1991: Bertram L Kasiske; Michael P O'Donnell; H Lee; Y Kim; William F Keane
Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats.
Kidney international 1991;39(6):1125-34.
1991: William F Keane; Bertram L Kasiske; Michael P O'Donnell; Y Kim
The role of altered lipid metabolism in the progression of renal disease: experimental evidence.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1991;17(5 Suppl 1):38-42.
1991: William F Keane; W S Mulcahy; Bertram L Kasiske; Y Kim; Michael P O'Donnell
Hyperlipidemia and progressive renal disease.
Kidney international. Supplement 1991;31():S41-8.
1991: Bertram L Kasiske; Michael P O'Donnell; Paul G Schmitz; William F Keane
The role of lipid abnormalities in the pathogenesis of chronic, progressive renal disease.
Advances in nephrology from the Necker Hospital 1991;20():109-25.
1990: William F Keane; Michael P O'Donnell; Bertram L Kasiske; Paul G Schmitz
Lipids and the progression of renal disease.
Journal of the American Society of Nephrology : JASN 1990;1(5 Suppl 2):S69-74.
1990: Michael P O'Donnell; Bertram L Kasiske; Paul G Schmitz; William F Keane
High protein intake accelerates glomerulosclerosis independent of effects on glomerular hemodynamics.
Kidney international 1990;37(5):1263-9.
1990: Bertram L Kasiske; Michael P O'Donnell; W Cowardin; William F Keane
Lipids and the kidney.
Hypertension 1990;15(5):443-50.
1990: Bertram L Kasiske; Michael P O'Donnell; Paul G Schmitz; Y Kim; William F Keane
Renal injury of diet-induced hypercholesterolemia in rats.
Kidney international 1990;37(3):880-91.
1990: Bertram L Kasiske; J A Velosa; C E Halstenson; P La Belle; A Langendörfer; William F Keane
The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1990;15(1):8-15.
1990: JA Opsahl; P A Abraham; William F Keane
Angiotensin-converting enzyme inhibitors in chronic renal failure.
Drugs 1990;39 Suppl 2():23-32.
1989: Paul G Schmitz; Bertram L Kasiske; Michael P O'Donnell; William F Keane
Lipids and progressive renal injury.
Seminars in nephrology 1989;9(4):354-69.
1989: David R P Guay; Walid Awni; C E Halstenson; M T Kenny; William F Keane; G R Matzke
Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.
Antimicrobial agents and chemotherapy 1989;33(11):2012-5.
1989: William F Keane; Bertram L Kasiske; Michael P O'Donnell; Paul G Schmitz
Therapeutic implications of lipid-lowering agents in the progression of renal disease.
The American journal of medicine 1989;87(5N):21N-24N.
1989: Bertram L Kasiske; Michael P O'Donnell; William F Keane
Fish oil diet decreases prostacyclin and increases resistance in isolated rat kidneys.
The American journal of physiology 1989;256(5 Pt 2):F843-51.
1989: Michael P O'Donnell; Bertram L Kasiske; William F Keane
Risk factors for glomerular injury in rats with genetic hypertension.
American journal of hypertension 1989;2(1):9-13.
1989: Bertram L Kasiske; Michael P O'Donnell; M P Cleary; William F Keane
Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats.
Kidney international 1989;35(1):40-7.
1988: P A Abraham; JA Opsahl; C E Halstenson; William F Keane
Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency.
Archives of internal medicine 1988;148(11):2358-62.
1988: C F Brummitt; Burt Sharp; Genya Gekker; William F Keane; Phillip K Peterson
Modulatory effects of beta-endorphin on interferon-gamma production by cultured peripheral blood mononuclear cells: heterogeneity among donors and the influence of culture medium.
Brain, behavior, and immunity 1988;2(3):187-97.
1988: JA Opsahl; P A Abraham; C E Halstenson; William F Keane
Correlation of office and ambulatory blood pressure measurements with urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in essential hypertension.
American journal of hypertension 1988;1(3 Pt 3):117S-120S.
1988: Bertram L Kasiske; Michael P O'Donnell; M P Cleary; William F Keane
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats.
Kidney international 1988;33(3):667-72.
1988: Bertram L Kasiske; Michael P O'Donnell; W J Garvis; William F Keane
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Circulation research 1988;62(2):367-74.
1988: P A Abraham; C E Halstenson; JA Opsahl; G R Matzke; William F Keane
Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain.
American journal of nephrology 1988;8(2):90-5.
1988: William F Keane; Bertram L Kasiske; Michael P O'Donnell
Hyperlipidemia and the progression of renal disease.
The American journal of clinical nutrition 1988;47(1):157-60.
1988: William F Keane; Bertram L Kasiske; Michael P O'Donnell
Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis.
American journal of nephrology 1988;8(4):261-71.
1987: C E Halstenson; P A Abraham; JA Opsahl; A N Chremos; William F Keane; G R Matzke
Disposition of famotidine in renal insufficiency.
Journal of clinical pharmacology 1987;27(10):782-7.
1987: Phillip K Peterson; B Sharp; Genya Gekker; C Brummitt; William F Keane
Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells.
The Journal of clinical investigation 1987;80(3):824-31.
1987: P A Abraham; JA Opsahl; C E Halstenson; A N Chremos; G R Matzke; William F Keane
The effect of famotidine on renal function in patients with renal insufficiency.
British journal of clinical pharmacology 1987;24(3):385-9.
1987: Phillip K Peterson; B Sharp; Genya Gekker; C Brummitt; William F Keane
Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(11):3907-12.
1987: William F Keane; Bertram L Kasiske; Michael P O'Donnell
The role of lipids in progressive glomerular disease.
Advances in experimental medicine and biology 1987;223():81-7.
1987: Bertram L Kasiske; Michael P O'Donnell; William F Keane
The obese Zucker rat model of glomerular injury in type II diabetes.
The Journal of diabetic complications 1987;1(1):26-9.